RecruitingNCT05906316

A Prospective, Multicenter, Single-arm MAC-PD Cohort: a NTM-NET and ESGMYC Collaborative Study


Sponsor

Radboud University Medical Center

Enrollment

100 participants

Start Date

Jul 1, 2023

Study Type

OBSERVATIONAL

Conditions

Summary

To gain insight in the effectiveness of, adherence and adjustments to guideline-based three-drug antimycobacterial therapy in patients with Mycobacterium avium complex pulmonary disease (MAC-PD) during the first 6 months of treatment.


Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a new treatment for people with mycobacterium avium complex pulmonary disease. The study is currently recruiting participants at 11 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.


Locations(11)

Oregon Science and Health University

Portland, Oregon, United States

UZ Leuven

Leuven, Belgium

University of Calgary

Calgary, Alberta, Canada

University Hospital Center Zagreb

Zagreb, Croatia

Aarhus University Hospital

Aarhus, Denmark

Rasmus Rude Laub

Hellerup, Denmark

University Hospital Frankfurt

Frankfurt, Germany

Fukujuji Hospital

Tokyo, Japan

Radboud University Medical Center

Nijmegen, Netherlands

Seoul National University Hospital

Seoul, South Korea

Hospital Clínic de Barcelona

Barcelona, Spain

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05906316


Related Trials